Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Effectiveness of Tixagevimab-cilgavimab for COVID-19 Prevention in Thai Solid Organ Transplant Recipients
TCTR20220801004Phase 4Completed
- Sponsor
- Faculty of Medicine Ramathibodi Hospital, Mahidol University
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by Faculty of Medicine Ramathibodi Hospital, Mahidol University. Started Aug 2022; status: completed.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220801004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220801004.